Zobrazeno 1 - 10
of 171
pro vyhledávání: '"Antiepileptogenesis"'
Autor:
Jacqueline A. French, Martina Bebin, Marc A. Dichter, Jerome Engel Jr., Adam L. Hartman, Sergiusz Jóźwiak, Pavel Klein, James McNamara Sr., Roy Twyman, Paul Vespa
Publikováno v:
Epilepsia Open, Vol 6, Iss 3, Pp 483-492 (2021)
Abstract This is a summary report of clinical and regulatory issues discussed at the 2018 NINDS workshop, entitled “Accelerating Therapies for Antiepileptogenesis and Disease Modification.” The intent of the workshop was to optimize and accelerat
Externí odkaz:
https://doaj.org/article/531730396fe34253a66a9b0c974ba20d
Autor:
Jerome Engel, Jr
Publikováno v:
Neurobiology of Disease, Vol 123, Iss , Pp 3-7 (2019)
Epilepsy is one of the most common brain disorders, causing serious disability and premature death worldwide. Approximately 1.2% of the U.S. population has active epilepsy, and 30 to 40% have seizures that do not respond to antiseizure drugs. There c
Externí odkaz:
https://doaj.org/article/392ac3660a734f80997c2310bdfc18ad
Publikováno v:
Neurobiology of Disease, Vol 123, Iss , Pp 42-58 (2019)
A biomarker is a characteristic that is measured as an indicator of normal biologic processes, pathogenic processes, or responses to an exposure or intervention, including therapeutic interventions. Biomarker modalities include molecular, histologic,
Externí odkaz:
https://doaj.org/article/799f11f55bff4bdd8dfc4a23d098fd96
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Asla Pitkänen, Noora Huusko, Xavier Ekolle Ndode-Ekane, Jenni Kyyriäinen, Anssi Lipponen, Anu Lipsanen, Alejandra Sierra, Tamuna Bolkvadze
Publikováno v:
Neurobiology of Disease, Vol 72, Iss , Pp 224-232 (2014)
Disease modification of epilepsy refers to the alleviation of epileptogenesis or comorbidities after genetic or acquired epileptogenic brain insults. There are currently 30 proof-of-concept experimental pharmacologic studies that have demonstrated so
Externí odkaz:
https://doaj.org/article/8f4ecbfa7d1043cf95c4ee94b3bed39a
Autor:
Yun Hwang, Shilpa D. Kadam
Publikováno v:
Epilepsy Currents
Autor:
Twyman Roy E, Jerome Engel, Pavel Klein, Marc A. Dichter, Sergiusz Jóźwiak, James O. McNamara, Adam L. Hartman, Martina Bebin, Jacqueline A. French, Paul M. Vespa
Publikováno v:
Epilepsia Open
Epilepsia Open, Vol 6, Iss 3, Pp 483-492 (2021)
Epilepsia Open, Vol 6, Iss 3, Pp 483-492 (2021)
This is a summary report of clinical and regulatory issues discussed at the 2018 NINDS workshop, entitled “Accelerating Therapies for Antiepileptogenesis and Disease Modification.” The intent of the workshop was to optimize and accelerate develop
Autor:
Gilles van Luijtelaar, Asht M. Mishra, Peter Edelbroek, Daniel Coman, Nikita Frankenmolen, Pauline Schaapsmeerders, Giulio Covolato, Nathan Danielson, Hannah Niermann, Kryzstof Janeczko, Anne Kiemeneij, Julija Burinov, Chhitij Bashyal, Madeline Coquillette, Annika Lüttjohann, Fahmeed Hyder, Hal Blumenfeld, Clementina M. van Rijn
Publikováno v:
Neurobiology of Disease, Vol 60, Iss , Pp 126-138 (2013)
The beneficial effects of chronic and early pharmacological treatment with ethosuximide on epileptogenesis were studied in a genetic absence epilepsy model comorbid for depression. It was also investigated whether there is a critical treatment period
Externí odkaz:
https://doaj.org/article/4578cdd33f1e4920bf374d245fe64fa8
Publikováno v:
Current Neuropharmacology
Although over 25 antiepileptic drugs (AEDs) have become currently available for clinical use, the incidence of epilepsy worldwide and the proportions of drug-resistant epilepsy among them are not significantly reduced during the past decades. Traditi
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.